Benkert, P; Meier, S; Schaedelin, S; Manouchehrinia, A; Yaldizli, Ö; Maceski, A; Oechtering, J; ... Zecca, C; + view all Benkert, P; Meier, S; Schaedelin, S; Manouchehrinia, A; Yaldizli, Ö; Maceski, A; Oechtering, J; Achtnichts, L; Conen, D; Derfuss, T; Lalive, PH; Mueller, C; Müller, S; Naegelin, Y; Oksenberg, JR; Pot, C; Salmen, A; Willemse, E; Kockum, I; Blennow, K; Zetterberg, H; Gobbi, C; Kappos, L; Wiendl, H; Berger, K; Sormani, MP; Granziera, C; Piehl, F; Leppert, D; Kuhle, J; Aeschbacher, S; Barakovic, M; Buser, A; Chan, A; Disanto, G; D'Souza, M; Du Pasquier, R; Findling, O; Galbusera, R; Hrusovsky, K; Khalil, M; Lorscheider, J; Mathias, A; Orleth, A; Radue, EW; Rahmanzadeh, R; Sinnecker, T; Subramaniam, S; Vehoff, J; Wellmann, S; Wuerfel, J; Zecca, C; - view fewer (2022) Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study. The Lancet Neurology , 21 (3) pp. 246-257. 10.1016/S1474-4422(22)00009-6.

Preview

Text Zetterberg_Benkert (1).pdf Download (797kB) | Preview

Abstract

Background: Serum neurofilament light chain (sNfL) is a biomarker of neuronal damage that is used not only to monitor disease activity and response to drugs and to prognosticate disease course in people with multiple sclerosis on the group level. The absence of representative reference values to correct for physiological age-dependent increases in sNfL has limited the diagnostic use of this biomarker at an individual level. We aimed to assess the applicability of sNfL for identification of people at risk for future disease activity by establishing a reference database to derive reference values corrected for age and body-mass index (BMI). Furthermore, we used the reference database to test the suitability of sNfL as an endpoint for group-level comparison of effectiveness across disease-modifying therapies. Methods: For derivation of a reference database of sNfL values, a control group was created, comprising participants with no evidence of CNS disease taking part in four cohort studies in Europe and North America. We modelled the distribution of sNfL concentrations in function of physiological age-related increase and BMI-dependent modulation, to derive percentile and Z score values from this reference database, via a generalised additive model for location, scale, and shape. We tested the reference database in participants with multiple sclerosis in the Swiss Multiple Sclerosis Cohort (SMSC). We compared the association of sNfL Z scores with clinical and MRI characteristics recorded longitudinally to ascertain their respective disease prognostic capacity. We validated these findings in an independent sample of individuals with multiple sclerosis who were followed up in the Swedish Multiple Sclerosis registry. Findings: We obtained 10 133 blood samples from 5390 people (median samples per patient 1 [IQR 1–2] in the control group). In the control group, sNfL concentrations rose exponentially with age and at a steeper increased rate after approximately 50 years of age. We obtained 7769 samples from 1313 people (median samples per person 6·0 [IQR 3·0–8·0]). In people with multiple sclerosis from the SMSC, sNfL percentiles and Z scores indicated a gradually increased risk for future acute (eg, relapse and lesion formation) and chronic (disability worsening) disease activity. A sNfL Z score above 1·5 was associated with an increased risk of future clinical or MRI disease activity in all people with multiple sclerosis (odds ratio 3·15, 95% CI 2·35–4·23; p<0·0001) and in people considered stable with no evidence of disease activity (2·66, 1·08–6·55; p=0·034). Increased Z scores outperformed absolute raw sNfL cutoff values for diagnostic accuracy. At the group level, the longitudinal course of sNfL Z score values in people with multiple sclerosis from the SMSC decreased to those seen in the control group with use of monoclonal antibodies (ie, alemtuzumab, natalizumab, ocrelizumab, and rituximab) and, to a lesser extent, oral therapies (ie, dimethyl fumarate, fingolimod, siponimod, and teriflunomide). However, longitudinal sNfL Z scores remained elevated with platform compounds (interferons and glatiramer acetate; p<0·0001 for the interaction term between treatment category and treatment duration). Results were fully supported in the validation cohort (n=4341) from the Swedish Multiple Sclerosis registry. Interpretation: The use of sNfL percentiles and Z scores allows for identification of individual people with multiple sclerosis at risk for a detrimental disease course and suboptimal therapy response beyond clinical and MRI measures, specifically in people with disease activity-free status. Additionally, sNfL might be used as an endpoint for comparing effectiveness across drug classes in pragmatic trials. Funding: Swiss National Science Foundation, Progressive Multiple Sclerosis Alliance, Biogen, Celgene, Novartis, Roche.

Download activity - last month

Export as CSVJSONXML

Download activity - last 12 months

Export as JSONCSVXML

Downloads by country - last 12 months

Export as CSVJSONXML

Archive Staff Only

View Item